Cardiff Oncology (NASDAQ:CRDF) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) issued its earnings results on Thursday. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02, Zacks reports. Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%.

Cardiff Oncology Stock Down 2.7%

CRDF traded down $0.02 on Thursday, reaching $0.74. The company’s stock had a trading volume of 140,076 shares, compared to its average volume of 1,026,652. The stock has a 50 day moving average of $1.05 and a two-hundred day moving average of $1.37. The company has a market capitalization of $57.96 million, a price-to-earnings ratio of -1.24 and a beta of 1.57. Cardiff Oncology has a fifty-two week low of $0.72 and a fifty-two week high of $3.31.

Analyst Upgrades and Downgrades

Several research analysts have commented on CRDF shares. HC Wainwright upgraded shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a report on Tuesday, September 15th. Wall Street Zen upgraded shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. William Blair cut shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cardiff Oncology presently has a consensus rating of “Hold” and an average target price of $7.50.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division. Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.